Tumor Vascular Permeability to a Nanoprobe Correlates to Tumor-Specific Expression Levels of Angiogenic Markers
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Vascular endothelial growth factor (VEGF) receptor-2 is the major mediator of the mitogenic, angiogenic, and vascular hyperpermeability effects of VEGF on breast tumors. Overexpression of VEGF and VEGF receptor-2 is associated with the degree of pathomorphosis of the tumor tissue and unfavorable prognosis. In this study, we demonstrate that non-invasive quantification of the degree of tumor vascular permeability to a nanoprobe correlates with the VEGF and its receptor levels and tumor growth. METHODOLOGY/PRINCIPAL FINDINGS: We designed an imaging nanoprobe and a methodology to detect the intratumoral deposition of a 100 nm-scale nanoprobe using mammography allowing measurement of the tumor vascular permeability in a rat MAT B III breast tumor model. The tumor vascular permeability varied widely among the animals. Notably, the VEGF and VEGF receptor-2 gene expression of the tumors as measured by qRT-PCR displayed a strong correlation to the imaging-based measurements of vascular permeability to the 100 nm-scale nanoprobe. This is in good agreement with the fact that tumors with high angiogenic activity are expected to have more permeable blood vessels resulting in high intratumoral deposition of a nanoscale agent. In addition, we show that higher intratumoral deposition of the nanoprobe as imaged with mammography correlated to a faster tumor growth rate. This data suggest that vascular permeability scales to the tumor growth and that tumor vascular permeability can be a measure of underlying VEGF and VEGF receptor-2 expression in individual tumors. CONCLUSIONS/SIGNIFICANCE: This is the first demonstration, to our knowledge, that quantitative imaging of tumor vascular permeability to a nanoprobe represents a form of a surrogate, functional biomarker of underlying molecular markers of angiogenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Angiogenesis as a therapeutic target
Ferrara, N., & Kerbel, R. S. (2005) · Nature · doi:10.1038/nature04483 · Cited by 2,653
Tumor microenvironment abnormalities: Causes, consequences, and strategies to normalize
Fukumura, D., & Jain, R. K. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21187 · Cited by 584
Cited by
X-ray-Computed Tomography Contrast Agents
Lusic, H., & Grinstaff, M. W. (2013) · Chemical Reviews · doi:10.1021/cr200358s · Cited by 1,108
Lee, N., Choi, S. H., & Hyeon, T. (2013) · Advanced Materials · doi:10.1002/adma.201300081 · Cited by 657
Shaping Cancer Nanomedicine: The Effect of Particle Shape on The In Vivo Journey of Nanoparticles
Toy, R., Peiris, P. M., Ghaghada, K. B., & Karathanasis, E. (2014) · Nanomedicine · doi:10.2217/nnm.13.191 · Cited by 570
Self-citationNanoparticle Characterization: State of the Art, Challenges, and Emerging Technologies
Cho, E. J., Holback, H., Liu, K. C., Abouelmagd, S. A., Park, J., & Yeo, Y. (2013) · Molecular Pharmaceutics · doi:10.1021/mp300697h · Cited by 382
Mediating Passive Tumor Accumulation through Particle Size, Tumor Type, and Location
Perry, J. L., Reuter, K. G., Luft, J. C., Pecot, C. V., Zamboni, W., & DeSimone, J. M. (2017) · Nano Letters · doi:10.1021/acs.nanolett.7b00021 · Cited by 255
Metadata
- Authors
- Karathanasis, E., Chan, L., Karumbaiah, L., McNeeley, K., D'Orsi, C. J., Annapragada, A. V., Sechopoulos, I., & Bellamkonda, R. V.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2009-06-09
- Volume
- 4
- Issue
- 6
- Pages
- e5843
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2021206870
- Cited by
- 74
- References
- 2
- FWCI
- 2.40
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.